Iron Deficiency Anemia: 6 Updated Practice Considerations
Evidence synthesis on ferritin thresholds, alternate-day oral iron dosing, IV iron indications, and gastrointestinal workup for primary care.
One-Minute Takeaway on Iron Deficiency Anemia
One-Minute Takeaway
- Iron deficiency anemia diagnosis benefits from updated ferritin thresholds — typically below 30 ng/mL in the absence of inflammation, with a higher cutoff (often 100 ng/mL) when inflammation, chronic kidney disease, or heart failure is present.
- Alternate-day oral iron dosing produces comparable or superior cumulative absorption to daily dosing with fewer gastrointestinal side effects, driven by hepcidin’s response to repeated dosing.
- IV iron has expanded indications: heart failure with iron deficiency (FAIR-HF, AFFIRM-AHF, HEART-FID), inflammatory bowel disease, dialysis-dependent CKD (PIVOTAL), and oral iron intolerance.
- All adult men and post-menopausal women with confirmed iron deficiency anemia warrant gastrointestinal evaluation; bidirectional endoscopy plus celiac serology is the standard approach.
- Common pitfalls include testing ferritin during inflammation, prescribing excess daily oral iron doses, and stopping treatment at hemoglobin normalization rather than at ferritin replenishment.
Why Iron Deficiency Anemia Matters in Primary Care
Iron deficiency anemia remains the most common nutritional deficiency worldwide and one of the most frequent abnormal laboratory findings encountered in primary care. It affects an estimated 5–10% of US adults and a substantially higher proportion of menstruating women, pregnant women, and patients with chronic disease.
Despite its frequency, several aspects of management have changed materially over the last decade. Ferritin thresholds have been recalibrated upward, alternate-day oral iron has emerged as a tolerability-improving alternative, IV iron has secured first-line status in heart failure and several other conditions, and gastrointestinal workup standards have been clarified.
For family physicians, iron deficiency anemia represents both a high-volume condition and one with multiple recent evidence updates. Older reflexes — tolerance of low ferritin in chronic disease, three-times-daily ferrous sulfate, deferral of IV iron to specialty referral, and inconsistent gastrointestinal workup — are increasingly out of step with current guidelines.
This evidence review organizes the changed practice landscape around six considerations relevant to routine primary care diagnosis and treatment of iron deficiency anemia.
What Evidence Was Reviewed
This synthesis draws on the Stoffel alternate-day dosing trials, the British Society of Gastroenterology 2021 guidelines, four landmark trials of IV iron in heart failure (FAIR-HF, CONFIRM-HF, AFFIRM-AHF, HEART-FID), the PIVOTAL trial in dialysis, the Camaschella NEJM review, and current WHO anemia diagnostic standards.
The table below summarizes the key evidence sources informing the comparative claims in this review.
| Study / Source | Design | n | Population | Intervention / Focus | Primary Outcome |
|---|---|---|---|---|---|
| Stoffel 2017 (Lancet Haematol) | RCT, crossover | 40 | Iron-depleted women | Alternate vs daily oral iron | Fractional iron absorption |
| Stoffel 2020 (Haematologica) | RCT | 62 | Iron-deficient anemic women | Alternate vs daily oral iron over 14 days | Cumulative iron absorption |
| BSG 2021 Guidelines (Snook) | Practice guideline | — | Adults with iron deficiency anemia | Diagnostic and workup approach | Ferritin thresholds, GI workup |
| FAIR-HF (Anker 2009) | RCT | 459 | HFrEF + iron deficiency | Ferric carboxymaltose IV vs placebo | Patient global assessment, NYHA class |
| CONFIRM-HF (Ponikowski 2015) | RCT | 304 | HFrEF + iron deficiency | Ferric carboxymaltose 1 yr vs placebo | 6-min walk distance change |
| AFFIRM-AHF (Ponikowski 2020) | RCT | 1,108 | Acute HF + iron deficiency at discharge | Ferric carboxymaltose IV vs placebo | HF hospitalization or CV death |
| HEART-FID (Mentz 2023) | RCT | 3,065 | HFrEF + iron deficiency | Ferric carboxymaltose IV vs placebo | Death, HF hospitalization, 6MWT composite |
| PIVOTAL (Macdougall 2019) | RCT | 2,141 | Hemodialysis patients | Proactive vs reactive IV iron sucrose | CV events, mortality |
| Camaschella 2015 (NEJM) | Narrative review | — | Adults | Diagnosis and treatment of IDA | Reference standard review |
| Auerbach 2016 (Am J Hematol) | Practice review | — | Adults | IV iron formulations and dosing | Reference standard review |
Key Findings on Iron Deficiency Anemia Diagnosis and Treatment
Consideration 1 — Ferritin Thresholds Have Been Recalibrated
The traditional ferritin cutoff of 15 ng/mL for iron deficiency anemia derives from older studies and has been revised upward in recent guidelines. The British Society of Gastroenterology 2021 guidelines recommend a threshold of 30 ng/mL in the absence of inflammation, with a higher cutoff (often 100 ng/mL) in patients with chronic inflammation, chronic kidney disease, or heart failure.
Sensitivity considerations matter clinically: at the 15 ng/mL threshold, sensitivity for iron deficiency is poor in patients with normal CRP and worse with concomitant inflammation, since ferritin functions as an acute-phase reactant. At 30 ng/mL, sensitivity improves substantially while preserving acceptable specificity.
Transferrin saturation below 20% supports iron deficiency in equivocal cases, particularly when ferritin is mid-range due to inflammation. Reticulocyte hemoglobin content below 28 pg, where available, provides additional discrimination for iron-restricted erythropoiesis and is increasingly used in heart failure and CKD populations.
Consideration 2 — Alternate-Day Oral Iron Improves Absorption and Tolerability
The Stoffel 2017 Lancet Haematology trial randomized 40 iron-depleted women to alternate-day or consecutive-day oral iron and demonstrated higher fractional absorption with alternate-day dosing. The mechanism is hepcidin’s induction following an iron dose, which transiently reduces absorption of subsequent doses given within 24 hours.
A 2020 follow-up trial by Stoffel and colleagues in iron-deficient anemic women confirmed greater cumulative iron absorption from alternate-day dosing over 14 days compared with daily dosing, with fewer reported gastrointestinal side effects.
Practical implementation in primary care: 60–120 mg of elemental iron (ferrous sulfate 325 mg contains approximately 65 mg of elemental iron) on alternate days produces comparable or superior absorption with fewer GI complaints than the same dose given daily. This finding is most relevant when oral iron is poorly tolerated or adherence to a daily regimen has been challenging.
Clinical pearl on iron deficiency anemia treatment: Splitting daily ferrous sulfate into two or three doses across a day generally does not improve absorption and worsens tolerability. Consolidating to a single morning dose, with alternate-day frequency in patients with GI side effects, is the more evidence-aligned approach.
Consideration 3 — IV Iron Indications Have Expanded
Intravenous iron formulations — including ferric carboxymaltose, iron isomaltoside (ferric derisomaltose), and iron sucrose — have expanded indications well beyond intolerance of oral iron.
Heart failure with iron deficiency: FAIR-HF, CONFIRM-HF, and AFFIRM-AHF demonstrated improvements in functional status, NYHA class, and 6-minute walk distance with IV ferric carboxymaltose in HFrEF patients with iron deficiency (defined as ferritin below 100 ng/mL, or ferritin 100–300 with TSAT below 20%). Effects on hospitalization are positive in AFFIRM-AHF and mixed in HEART-FID’s primary composite, with consistent functional benefit.
Inflammatory bowel disease: IV iron is preferred in active IBD due to oral iron’s poor absorption and potential exacerbation of GI inflammation. Major IBD guideline bodies endorse IV iron as first-line in this setting.
Dialysis-dependent CKD: The PIVOTAL trial demonstrated that proactive high-dose IV iron in hemodialysis patients reduced cardiovascular events compared with reactive lower-dose strategies, with no signal of harm and a strong all-cause mortality trend.
Other indications: Persistent oral iron intolerance, post-bariatric surgery, untreated celiac disease awaiting confirmation, and severe iron deficiency anemia where rapid repletion is preferred over the months-long timeline of oral therapy.
Consideration 4 — GI Evaluation Is Standard for Specific Populations
All adult men and post-menopausal women with confirmed iron deficiency anemia warrant evaluation for gastrointestinal blood loss. The British Society of Gastroenterology 2021 guidelines specify a standard approach:
- Bidirectional endoscopy: EGD plus colonoscopy in men of any age and post-menopausal women.
- Celiac serology: Tissue transglutaminase IgA plus total IgA in essentially all patients with iron deficiency anemia.
- Small bowel evaluation: Capsule endoscopy or CT enterography if EGD and colonoscopy are unrevealing and iron deficiency persists or recurs.
- Helicobacter pylori testing: Considered in unexplained iron deficiency or where EGD findings suggest gastritis.
Pre-menopausal women with menorrhagia and no other red flags can often be managed with iron repletion plus gynecologic evaluation, with GI workup reserved for those with persistent or recurrent iron deficiency anemia despite adequate menstrual evaluation, family history concerns, or alarm symptoms (weight loss, change in bowel habit, melena, hematochezia).
Consideration 5 — Adjunctive Testing Improves Diagnostic Accuracy
Ferritin alone is insufficient in many primary care iron deficiency anemia scenarios, particularly when inflammation, chronic disease, or atypical presentations cloud interpretation. Useful complementary tests include:
- CRP or ESR: Identifies inflammation that may falsely elevate ferritin.
- Transferrin saturation (TSAT): Below 20% supports iron deficiency, particularly when ferritin is equivocal.
- Total iron binding capacity (TIBC): Elevated in iron deficiency, low or normal in inflammation.
- Soluble transferrin receptor (sTfR): Available in some settings; not affected by inflammation, useful in mixed states.
- Reticulocyte hemoglobin content (CHr): Real-time marker of iron availability for erythropoiesis.
- Celiac serology: Iron deficiency is a frequent presentation of celiac disease, and serology should be routine in unexplained cases.
Combining ferritin with at least one inflammation marker substantially improves sensitivity and specificity in mixed inflammatory states common in older adults and patients with multiple chronic conditions.
Consideration 6 — Common Pitfalls to Avoid
Several pitfalls are well-documented in iron deficiency anemia management and worth explicit avoidance:
- Diagnostic pitfalls: Relying on ferritin alone during acute illness or chronic inflammation; missing iron deficiency in patients with apparently normal ferritin and elevated CRP; not repeating testing if initial values are equivocal.
- Oral treatment pitfalls: Prescribing high daily doses (e.g., three tablets daily of ferrous sulfate 325 mg) which paradoxically reduces total absorption via hepcidin upregulation; mid-meal dosing reducing absorption; co-administration with calcium, dairy, or proton pump inhibitors.
- Monitoring pitfalls: Discontinuing oral iron at hemoglobin normalization rather than at ferritin normalization (typically requiring 3–6 additional months of treatment to fully replenish stores).
- Workup pitfalls: Treating iron deficiency anemia in men or post-menopausal women without GI evaluation; failing to test for celiac disease in unexplained cases; over-relying on a single normal ferritin to rule out iron deficiency in inflammatory states.
A simple practical framework for ferritin interpretation in primary care:
- Ferritin < 30 ng/mL: Iron deficiency in essentially all settings (assuming no recent transfusion or IV iron).
- Ferritin 30–100 ng/mL: Likely iron deficiency if CRP normal; obtain TSAT to clarify if equivocal.
- Ferritin 100–300 ng/mL with TSAT < 20% and chronic disease: Functional iron deficiency in heart failure, CKD, or IBD — supports treatment in those contexts.
- Ferritin > 300 ng/mL with elevated CRP: Iron deficiency unlikely; investigate for alternative causes of anemia.
The 100 ng/mL threshold in heart failure and CKD reflects the way these conditions induce inflammation and hepcidin, not different iron biology. Functional iron deficiency at higher ferritin still benefits from iron repletion in selected settings.
An evidence-aligned alternate-day oral iron regimen:
- Dose: Ferrous sulfate 325 mg (≈65 mg elemental iron) — one tablet on alternate days, typically morning.
- Timing: 30–60 minutes before breakfast on dosing days, with vitamin C (orange juice, 100–200 mg ascorbate) to enhance absorption.
- Avoid: Calcium, dairy, antacids, and tea or coffee within 1 hour of dosing; proton pump inhibitors reduce absorption when avoidable.
- Duration: 3–6 months after hemoglobin normalization to replenish stores.
- Monitoring: Hemoglobin and reticulocyte response at 2 weeks; ferritin at 8–12 weeks; full reassessment at 3–6 months.
For patients with severe oral iron intolerance, ferrous gluconate or ferrous fumarate are alternatives; iron polymaltose has fewer GI effects but lower absorption.
Current preparations relevant to family practice:
- Ferric carboxymaltose: Up to 750 mg per infusion in the US (1,000 mg in Europe); single or two-dose regimens commonly replete most patients. Hypophosphatemia is a recognized adverse effect requiring monitoring in repeat dosers.
- Ferric derisomaltose (iron isomaltoside): Single-dose total replacement up to 20 mg/kg; lower hypophosphatemia rates than ferric carboxymaltose.
- Iron sucrose: Smaller per-infusion doses (200–300 mg); requires multiple visits but well-established safety profile.
- Ferumoxytol: Two doses for total replacement; carries a more cautious labeling regarding hypersensitivity.
Modern IV iron preparations rarely cause anaphylaxis (estimated < 1 per 200,000 with ferric carboxymaltose) and most can be administered in primary care or infusion-suite settings without hospitalization. Premedication is generally not required.
Standard workup for confirmed iron deficiency anemia in adults:
- Men of any age: Bidirectional endoscopy (EGD + colonoscopy) plus celiac serology.
- Post-menopausal women: Bidirectional endoscopy plus celiac serology.
- Pre-menopausal women with menorrhagia: Iron repletion and gynecologic evaluation; reserve GI workup for persistent or recurrent IDA, alarm features, or family history concerns.
- Pregnancy: Iron repletion; defer most invasive workup post-partum unless alarm features.
- Patients with prior negative bidirectional endoscopy and persistent IDA: Capsule endoscopy or CT enterography for small bowel evaluation.
Always include celiac serology — iron deficiency is a frequent presentation of celiac disease, and missed diagnoses prolong both the anemia and other complications.
Four large RCTs frame the heart failure indication:
- FAIR-HF (2009): Demonstrated symptomatic and functional improvement with ferric carboxymaltose in HFrEF.
- CONFIRM-HF (2015): Confirmed sustained 6-minute walk distance improvement at 1 year.
- AFFIRM-AHF (2020): Showed reduction in HF hospitalization (with COVID-related caveats on the primary composite) when initiated at hospital discharge.
- HEART-FID (2023): Did not meet its hierarchical composite primary endpoint but showed numerical benefit on functional and hospitalization components.
The synthesis: IV iron in HFrEF with iron deficiency consistently improves symptoms and functional capacity; the hospitalization benefit is real but smaller and less consistent than the symptom-quality-of-life signal.
Quality & Consistency of Evidence on Iron Deficiency Anemia
The evidence base on iron deficiency anemia diagnosis and treatment is strong across most domains, with several large landmark RCTs in IV iron and consistent observational and physiology-based evidence supporting updated diagnostic thresholds.
What the Evidence on Iron Deficiency Anemia Does Not Show
Several specific gaps remain in the iron deficiency anemia evidence base. Naming them clearly helps clinicians communicate uncertainty to patients and prioritize where ongoing research will refine practice.
Specific Evidence Gaps
- Optimal ferritin threshold in chronic inflammation: The 100 ng/mL cutoff is operationally useful but lacks dedicated RCT confirmation across diverse inflammatory conditions.
- Alternate-day dosing in men and pregnancy: Stoffel trials enrolled non-pregnant women; generalization to men, pregnancy, and pediatric populations is reasonable but not directly tested.
- Long-term outcomes with alternate-day dosing: Most evidence is short-term; multi-year retention and stores replenishment data are limited.
- Direct head-to-head IV iron formulations: Comparative effectiveness and safety across ferric carboxymaltose, ferric derisomaltose, and iron sucrose is incomplete.
- IV iron in HFpEF subgroups: Most heart failure trial evidence centers on HFrEF; HFpEF-specific signals are emerging but less mature.
- Hypophosphatemia consequences: Clinical sequelae of repeated ferric carboxymaltose-induced hypophosphatemia in primary care populations are not fully characterized.
- Pre-menopausal women with persistent IDA: When to escalate from menstrual management to GI workup remains a judgment call without strong randomized guidance.
- Pediatric iron deficiency anemia: Optimal dosing, alternate-day applicability, and long-term cognitive outcomes need contemporary trial data.
- IV iron in heart failure mortality: Whether IV iron reduces all-cause or CV mortality, beyond functional and hospitalization endpoints, is not established.
Practical Implications
Based on the current evidence on iron deficiency anemia, the following considerations may help structure diagnostic and treatment decisions in family practice. These are framed as evidence-supported considerations rather than directive recommendations.
Ferritin Below 30 ng/mL Defines Most Iron Deficiency
Updated thresholds have replaced the older 15 ng/mL cutoff. Use a higher threshold (often 100 ng/mL) when inflammation, chronic kidney disease, or heart failure is present, and add CRP or transferrin saturation in equivocal cases.
Alternate-Day Oral Iron Often Outperforms Daily
Stoffel trials demonstrate comparable or superior cumulative absorption with fewer GI side effects. Particularly valuable when adherence to daily dosing has failed or oral iron has been poorly tolerated.
IV Iron Is First-Line in Heart Failure With Iron Deficiency
FAIR-HF, AFFIRM-AHF, CONFIRM-HF, and HEART-FID collectively support IV ferric carboxymaltose for symptomatic and functional improvement; effects on hospitalization are real but more modest.
GI Workup Standard in Men and Post-Menopausal Women
Bidirectional endoscopy plus celiac serology forms the standard approach. Selective workup is acceptable in pre-menopausal women without alarm features when menstrual loss explains the anemia.
Combine Ferritin With CRP to Avoid Inflammation Confusion
Adjunctive testing — CRP, transferrin saturation, and where available reticulocyte hemoglobin content or soluble transferrin receptor — improves diagnostic accuracy when ferritin is equivocal in chronic disease.
Continue Treatment Beyond Hemoglobin Normalization
Iron stores require an additional 3–6 months of treatment after hemoglobin normalizes to fully replenish; ferritin should be the treatment endpoint, not hemoglobin alone.
Implementation Considerations
The most common iron deficiency anemia management pitfalls in primary care are stopping treatment too early, prescribing too much oral iron too often, and missing inflammation-masked deficiency by relying on a single normal-appearing ferritin. A simple workflow — CBC plus ferritin and CRP at diagnosis, alternate-day oral iron with a single morning dose, follow-up Hb at 2–4 weeks and ferritin at 3–6 months, GI evaluation triggered by patient-specific criteria — addresses the most frequent errors.
Evidence Grade & Bottom Line
Overall Evidence Grade: STRONG for ferritin-based diagnosis with updated thresholds, alternate-day oral iron absorption advantages, IV iron functional benefit in HFrEF and IBD, and standard GI workup in men and post-menopausal women. MODERATE for IV iron in dialysis and the higher ferritin threshold in inflammation. MIXED for IV iron’s effect on heart failure hospitalization composites.
Bottom Line
- Ferritin thresholds for iron deficiency anemia have moved from the older 15 ng/mL to typically 30 ng/mL without inflammation and 100 ng/mL with chronic inflammation, CKD, or heart failure — reflecting ferritin’s behavior as an acute-phase reactant.
- Alternate-day oral iron is at least as effective as daily dosing for cumulative absorption, with better tolerability — making it the more evidence-aligned default in primary care.
- IV iron has expanded indications including heart failure with iron deficiency, IBD, and dialysis-dependent CKD; modern formulations are safe enough for non-specialty settings.
- Bidirectional endoscopy plus celiac serology remains standard workup in men and post-menopausal women with confirmed iron deficiency anemia; pre-menopausal women with menorrhagia and no red flags can be managed less invasively.
- Treatment should continue 3–6 months beyond hemoglobin normalization to replenish iron stores, with ferritin — not hemoglobin alone — as the treatment endpoint.
Article Information & References
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Snook J, Bhala N, Beales ILP, et al. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. 2021;70(11):2030–2051. DOI: 10.1136/gutjnl-2021-325210
- Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017;4(11):e524–e533. DOI: 10.1016/S2352-3026(17)30182-5
- Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. 2020;105(5):1232–1239. DOI: 10.3324/haematol.2019.220830
- Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832–1843. DOI: 10.1056/NEJMra1401038
- Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–2448. DOI: 10.1056/NEJMoa0908355
- Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657–668. DOI: 10.1093/eurheartj/ehu385
- Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895–1904. DOI: 10.1016/S0140-6736(20)32339-4
- Mentz RJ, Garg J, Rockhold FW, et al. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med. 2023;389(11):975–986. DOI: 10.1056/NEJMoa2304968
- Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447–458. DOI: 10.1056/NEJMoa1810742
- Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31–38. DOI: 10.1002/ajh.24201
- Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10):1309–1316. DOI: 10.1136/gut.2010.228874
- Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021;397(10270):233–248. DOI: 10.1016/S0140-6736(20)32594-0
- Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9(3):211–222. DOI: 10.1093/ecco-jcc/jju009
- Schaefer B, Tobiasch M, Wagner S, et al. Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. Bone. 2022;154:116202. DOI: 10.1016/j.bone.2021.116202
- World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. WHO/NMH/NHD/MNM/11.1. Geneva: WHO; 2011. DOI: 10.1002/14651858.WHO11